LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Corcept Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

73.21 -1.43

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

72.52

Max

75.47

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-9.8M

21M

Pardavimai

-25M

157M

P/E

Sektoriaus vid.

64.591

50.291

Pelnas, tenkantis vienai akcijai

0.169

Pelno marža

13.069

Darbuotojai

500

EBITDA

-22M

3.4M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+87.45% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-28

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

165M

7.9B

Ankstesnė atidarymo kaina

74.64

Ankstesnė uždarymo kaina

73.21

Naujienos nuotaikos

By Acuity

49%

51%

157 / 380 reitingas Healthcare

Corcept Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-27 20:51; UTC

Uždarbis

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025-06-27 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-27 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-06-27 20:48; UTC

Rinkos pokalbiai

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

2025-06-27 20:46; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-06-27 20:46; UTC

Rinkos pokalbiai

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

2025-06-27 19:31; UTC

Rinkos pokalbiai

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

2025-06-27 19:19; UTC

Rinkos pokalbiai

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

2025-06-27 19:16; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025-06-27 18:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-27 18:42; UTC

Rinkos pokalbiai

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

2025-06-27 18:39; UTC

Rinkos pokalbiai
Uždarbis

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

2025-06-27 18:29; UTC

Rinkos pokalbiai

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

2025-06-27 18:18; UTC

Rinkos pokalbiai

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

2025-06-27 18:16; UTC

Rinkos pokalbiai

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

2025-06-27 17:16; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

2025-06-27 17:08; UTC

Uždarbis

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

2025-06-27 16:52; UTC

Įsigijimai, susijungimai, perėmimai

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

2025-06-27 16:22; UTC

Uždarbis

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025-06-27 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-06-27 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-27 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-27 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-06-27 15:59; UTC

Rinkos pokalbiai

Gold Futures Slump on Improving Risk Appetite -- Market Talk

2025-06-27 15:56; UTC

Rinkos pokalbiai

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Akcijų palyginimas

Kainos pokytis

Corcept Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

87.45% į viršų

12 mėnesių prognozė

Vidutinis 139.33 USD  87.45%

Aukščiausias 145 USD

Žemiausias 131 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corcept Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

4

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

157 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.